1 / 28

Prostate Cancer Screening Risk Management

Prostate Cancer Screening Risk Management. Prostate cancer European Study – Screening and Prostate-Cancer Mortality a Randomised Trial Why do we not have a screening programme? How do we manage PSA concerns?. Prostate Cancer. Most common cancer in males

sara-kent
Télécharger la présentation

Prostate Cancer Screening Risk Management

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prostate CancerScreening Risk Management

  2. Prostate cancer • European Study – Screening and Prostate-Cancer Mortality a Randomised Trial • Why do we not have a screening programme? • How do we manage PSA concerns?

  3. Prostate Cancer • Most common cancer in males • 2nd most common case of cancer deaths in males • 5 yr survival • 1971-1975  31% • 2000-2001  71%

  4. Pathophysiology • 95% Adenocarcinomas • 4% TCC • 70% peripheral • 15% central zone • 15% Transitional zone • T1-4 • Gleason score

  5. Risk Factors Age

  6. FH • 1st degree rel.  2x risk • Above rel <60  4x risk • Diet • Lycopenes + selenium decrease risk • Calcium increases risk • Obesity

  7. Ethnicity • Black African/ Caribbean  highest risk • White • Asian  Lowest risk

  8. Prostate Specific Antigen Elevated by: Ejaculation ~ for 48hrs Exercise ~ for 48hrs PR exam ~ for 1wk Prostate Biopsy ~ for 6wks UTI ~ for months BPH Prostate Cancer • Glycoprotein • Released from normal and malignant cells • Size • Age

  9. Prostate Specific Antigen Benefits Limitations Not specific No ca in 2/3 of elevated PSA Anxiety provoking Detection of clinically insignificant cancers May be falsely reassuring Approx 1/6 normal PSA may have prostate cancer Not helpful in identifying aggressive tumours • Nice and easy • Early detection • Repeat testing valuable Raaijmakers et al 2004

  10. Investigations Treatment Options Watchful waiting Active Monitoring Radical Prostatectomy Radiotherapy (ext beam / brachytherapy) High intensity focused USS Cryotherapy Hormonal therapy • Trans Rectal USS • TRUS guided biopsy • CT • MRI

  11. Why do we not have a screening programme?

  12. Screening and Prostate-cancer Mortality in a Randomised European Study – NEJM Mar 2009 • Multicentre Trial – Italy, Finland, Sweden, Netherlands, Belgium, Switzerland, Spain • 1990 - 2006 • 182,000 men 50-74 yrs • 4 yearly PSA vs control • Outcome = Mortality rate

  13. Results • Median follow up 9 years • 82% acceptance of screening • Cumulative incidence of prostate ca • Screening group 8.2% • Control group 4.8% • Mortality • Screening group ~ 3/1000 • Control group ~ 3.7/1000 • Rate ratio 0.8

  14. Conclusions • 20% reduction in deaths • To prevent 1 death: • Screen 1410 • Treat 48 additional px • Rate of over diagnosis as high as 50% NEJM Volume 360:1320-1328 J Natl Cancer Inst 2003;95:868-878

  15. Why do we not have a screening programme?

  16. Screening programme principles • The condition should be an important health problem. • The natural history of the disease should be adequately understood. • There should be a latent stage of the disease. • There should be a test or examination for the condition. • The test should be acceptable to the population. • There should be a treatment for the condition. • There should be an agreed policy on who to treat. • Facilities for diagnosis and treatment should be available. • The total cost of finding a case should be economically balanced in relation to medical expenditure as a whole. • Case-finding should be a continuous process, not just a "once and for all" project.

  17. PSA Informed Choice Programme

  18. Future • PSA factors • Velocity • Density • Proportions • Prostate Cancer 3 PCA3

  19. Further Info • http://www.cancerscreening.nhs.uk/index.html • http://info.cancerresearchuk.org/cancerstats/types/prostate/?a=5441 • http://content.nejm.org/cgi/content/full/NEJMoa0810084#R30

  20. Question time

More Related